Pannex Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pannex Therapeutics Inc. - overview
Established
2020
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2020, Pannex Therapeutics Inc. , is a pre-clinical stage biotech company that focuses on the development of novel drugs, intended for the treatment of various therapeutic areas and conditions. The company was founded by David Bravo (CEO), Thomas Gerlach, Gerhard Gross, and Jordan Marrocco, and in October 2021, Pannex Therapeutics Inc raised seed funding from SOSV. The firm is primarily focused on developing a therapeutic platform that blocks Pannexin 1 (Panx 1) channels, a pharmacological target linked to chronic pain.
Pannexin 1 blockers developed by the company are designed to target a variety of therapeutic regions, including cardiovascular, inflammatory, pulmonary, and CNS, allowing for the treatment of disorders such as autism, pain, cancer, epilepsy, migraine, and inflammation.
Current Investors
SOSV
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Cardiology
Website
www.pannextherapeutics.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.